Intrapleural fibrinolytic treatment of multiloculated pediatric empyemas.
Our objective was to compare the efficacy of adjunctive intrapleural fibrinolytic agents (IPFA) (streptokinase, urokinase) on fibrinopurulent stage empyema and chronic stage empyema in children. IPFA were used in 78 pediatric patients with empyema (36 fibrinopurulent stage empyemas, 42 chronic stage empyemas) between December 1994 and September 2002. Pleural biopsy was done for staging in all cases. Streptokinase 250,000 units in 100 ml normal saline (62 patients) or 100,000 units urokinase in 100 ml normal saline (16 patients) was instilled daily into the patient's chest tube, and the tube was clamped for 4 h, followed by suction. This treatment was continued daily for 2-8 days until resolution was demonstrated by chest radiographs and/or computed chest tomography. Success of treatment was 97.2% (complete response 24/36, partial response 11/36) in the fibrinopurulent stage and 9.4% (complete response 2/42, partial response 2/42) in chronic empyema cases. In one patient with fibrinopurulent empyema, the treatment was stopped due to allergic reaction and pleural hemorrhage; this patient died 1 day later in a septic condition. Although an invasive method, the pleural biopsy technique may be an alternative way of more properly staging thoracic empyema in selected children in whom staging based on radiographic and biochemical findings is doubtful. Intrapleural fibrinolytic treatment is an effective and safe therapy of choice and may have significant benefit in most children with fibrinopurulent phase empyema, except for those with bronchopleural fistula. IPFA do not seem to be effective in children with chronic phase empyema.
Ulkü
Refik
R
Department of Thoracic Surgery, Dicle University School of Medicine, 21280, Diyarbakir, Turkey. Refiku@dicle.edu.tr
Onen
Abdurrahman
A
Onat
Serdar
S
Kilinç
Nihal
N
Ozçelik
Cemal
C
D000293:Adolescent; D001706:Biopsy; D015505:Chest Tubes; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004342:Drug Hypersensitivity / Q000209:etiology; D016724:Empyema, Pleural / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005337:Fibrin / Q000037:antagonists & inhibitors; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007223:Infant; D008297:Male; D010995:Pleural Diseases / Q000209:etiology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000473:pathology; D013300:Streptokinase / Q000008:administration & dosage / Q000627:therapeutic use; D013396:Suction; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D005337:Fibrin; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator